Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIV-3: Therapeutics for Hospitalized COVID-19
NCT04501978Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2020
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies, Prodrugs/Conditional Activator Small Molecules, Carrier/Scaffold Proteins
- Countries
- 10
01
Overview
A Phase 3 trial of bamlanivimab, sotrovimab, amubarvimab, romlusevimab, tixagevimab in coronavirus disease 2019 (COVID-19), sponsored by National Institute of Allergy and Infectious Diseases. Started Aug 2020; status: completed.
02
Drugs
bamlanivimabsotrovimabamubarvimabromlusevimabtixagevimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04501978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04501978.